ResMed up on bullish analyst notes after solid quarter
ResMed (ASX:RMD) is still batting eyelashes at brokers, with Ord Minnett reaffirming its @Buy” rating following what it called a @solid” quarterly performance.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headl...
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No Corporate Spotlight currently available.